Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Present at the Q2 Investor Summit Conference

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
April 20, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
March 23, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
March 08, 2022 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
February 28, 2022 16:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...
January 27, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
January 18, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
December 22, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
December 06, 2021 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
November 24, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”

SEATTLE, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right